Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel

Long-term Follow-up (LTFU) of Study Participants Who Received Azer-Cel, An Allogeneic Chimeric Antigen Receptor T-Cell Product, in a TG Therapeutics, Inc., Clinical Study

The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.

Inclusion Criteria:

1. Received at least 1 dose of azer-cel in TG-Azercel -101 study.
2. Signed informed consent form (ICF).
3. Willingness and ability to adhere to the study schedule and all other protocol requirements.

Exclusion Citeria:

1. No unique exclusion criteria apply to this study.